Suppr超能文献

大麻素受体 1(CB1)拮抗剂增强肥胖小鼠的葡萄糖利用并激活棕色脂肪组织。

Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.

机构信息

Metabolic Diseases Institute, University of Cincinnati, 2140 East Galbraith Road, Building B, Room 332, Cincinnati, OH 45237-1625, USA.

出版信息

Diabetologia. 2011 Dec;54(12):3121-31. doi: 10.1007/s00125-011-2302-6. Epub 2011 Oct 11.

Abstract

AIMS/HYPOTHESIS: We examined the physiological mechanisms by which cannabinoid receptor 1 (CB1) antagonism improves glucose metabolism and insulin sensitivity independent of its anorectic and weight-reducing effects, as well as the effects of CB1 antagonism on brown adipose tissue (BAT) function.

METHODS

Three groups of diet-induced obese mice received for 1 month: vehicle; the selective CB1 antagonist SR141716; or vehicle/pair-feeding. After measurements of body composition and energy expenditure, mice underwent euglycaemic-hyperinsulinaemic clamp studies to assess in vivo insulin action. In separate cohorts, we assessed insulin action in weight-reduced mice with diet-induced obesity (DIO), and the effect of CB1 antagonism on BAT thermogenesis. Surgical denervation of interscapular BAT (iBAT) was carried out in order to study the requirement for the sympathetic nervous system in mediating the effects of CB1 antagonism on BAT function.

RESULTS

Weight loss associated with chronic CB1 antagonism was accompanied by increased energy expenditure, enhanced insulin-stimulated glucose utilisation, and marked activation of BAT thermogenesis. Insulin-dependent glucose uptake was significantly increased in white adipose tissue and BAT, whereas glycogen synthesis was increased in liver, fat and muscle. Despite marked weight loss in the mice, SR141716 treatment did not improve insulin-mediated suppression of hepatic glucose production nor increase skeletal muscle glucose uptake. Denervation of iBAT blunted the effect of SR141716 on iBAT differentiation and insulin-mediated glucose uptake.

CONCLUSIONS/INTERPRETATION: Chronic CB1 antagonism markedly enhances insulin-mediated glucose utilisation in DIO mice, independent of its anorectic and weight-reducing effects. The potent effect on insulin-stimulated BAT glucose uptake reveals a novel role for CB1 receptors as regulators of glucose metabolism.

摘要

目的/假设:我们研究了大麻素受体 1 (CB1) 拮抗剂改善葡萄糖代谢和胰岛素敏感性的生理机制,这些作用独立于其厌食和减重作用,以及 CB1 拮抗剂对棕色脂肪组织 (BAT) 功能的影响。

方法

三组饮食诱导肥胖的小鼠接受了为期 1 个月的治疗:载体;选择性 CB1 拮抗剂 SR141716;或载体/配对喂养。在测量身体成分和能量消耗后,小鼠进行了正常血糖高胰岛素钳夹研究,以评估体内胰岛素作用。在另一组实验中,我们评估了饮食诱导肥胖(DIO)小鼠体重减轻后的胰岛素作用,以及 CB1 拮抗剂对 BAT 产热的影响。对肩胛间 BAT(iBAT)进行了外科去神经支配,以研究交感神经系统在介导 CB1 拮抗剂对 BAT 功能的影响中的作用。

结果

慢性 CB1 拮抗剂治疗伴随的体重减轻伴随着能量消耗增加、胰岛素刺激的葡萄糖利用增强和 BAT 产热的显著激活。胰岛素依赖性葡萄糖摄取在白色脂肪组织和 BAT 中显著增加,而糖原合成在肝脏、脂肪和肌肉中增加。尽管小鼠体重明显减轻,但 SR141716 治疗并没有改善胰岛素介导的肝葡萄糖产生抑制,也没有增加骨骼肌葡萄糖摄取。iBAT 去神经支配削弱了 SR141716 对 iBAT 分化和胰岛素介导的葡萄糖摄取的影响。

结论/解释:慢性 CB1 拮抗剂显著增强了 DIO 小鼠中胰岛素介导的葡萄糖利用,独立于其厌食和减重作用。对胰岛素刺激的 BAT 葡萄糖摄取的强烈影响揭示了 CB1 受体作为葡萄糖代谢调节剂的新作用。

相似文献

1
Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.
Diabetologia. 2011 Dec;54(12):3121-31. doi: 10.1007/s00125-011-2302-6. Epub 2011 Oct 11.
6
Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
Obesity (Silver Spring). 2009 Aug;17(8):1641-5. doi: 10.1038/oby.2009.84. Epub 2009 Mar 26.
9
The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure.
Obesity (Silver Spring). 2009 Feb;17(2):254-61. doi: 10.1038/oby.2008.509. Epub 2008 Dec 4.

引用本文的文献

3
Emerging mechanisms of organ crosstalk: The role of oxylipins.
Nutr Bull. 2025 Mar;50(1):12-29. doi: 10.1111/nbu.12726. Epub 2024 Dec 10.
6
Characterization of the effects of cannabinoid receptor deletion on energy metabolism in female C57BL mice.
Front Endocrinol (Lausanne). 2024 Jun 19;15:1386230. doi: 10.3389/fendo.2024.1386230. eCollection 2024.
8
Changes in plasma endocannabinoids concentrations correlate with 18F-FDG PET/MR uptake in brown adipocytes in humans.
Front Mol Biosci. 2023 Jul 26;10:1073683. doi: 10.3389/fmolb.2023.1073683. eCollection 2023.
9
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
J Endocrinol Invest. 2023 Nov;46(11):2213-2236. doi: 10.1007/s40618-023-02125-0. Epub 2023 Jun 28.

本文引用的文献

1
Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice.
Diabetes. 2011 Jul;60(7):2000-7. doi: 10.2337/db10-0789. Epub 2011 May 20.
3
Brown adipose tissue activity controls triglyceride clearance.
Nat Med. 2011 Feb;17(2):200-5. doi: 10.1038/nm.2297. Epub 2011 Jan 23.
4
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
J Clin Invest. 2010 Aug;120(8):2953-66. doi: 10.1172/JCI42551. Epub 2010 Jul 26.
6
Transcriptional control of brown fat development.
Cell Metab. 2010 Apr 7;11(4):257-62. doi: 10.1016/j.cmet.2010.03.005.
8
Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.
Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1162-70. doi: 10.1152/ajpendo.00169.2009. Epub 2009 Sep 1.
9
Functional brown adipose tissue in healthy adults.
N Engl J Med. 2009 Apr 9;360(15):1518-25. doi: 10.1056/NEJMoa0808949.
10
Identification and importance of brown adipose tissue in adult humans.
N Engl J Med. 2009 Apr 9;360(15):1509-17. doi: 10.1056/NEJMoa0810780.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验